Terminated
PHASE4
INTERVENTIONAL
NCT01673984
GP Extended Action Triptorelin
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this study is to demonstrate that treatment with a 6-monthly injection of hormone therapy is as good and as well tolerated as the standard 3-monthly hormone therapy injections available for treating prostate cancer. The study will also aim to answer whether both doctors and patients would prefer treatment with a 6-monthly injection rather than injections every 3 months.
Interventions
Name:
Decapeptyl® SR 22.5mg
Type:
DRUG
Description:
22.5mg, intramuscular injection, given on day 1 / month 0 \& month 6 (+/- 7 days).
Name:
Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg
Type:
DRUG
Description:
For Decapeptyl® SR 11.25mg: 11.25 mg, intramuscular injection For Prostap® 3 DCS 11.25mg: 11.25mg, depot injected subcutaneously For Zoladex® LA 10.8mg: 10.8mg, depot injected subcutaneously into anterior abdominal wall
Primary Outcomes
Measure:
Percentage of Participants Maintaining Biochemical Castration
TimeFrame:
6 months
Description:
Patients with serum total testosterone (STT) level lower than 0.5 ng/mL after 6 months of treatment.
Trial Information
NCT ID
NCT01673984
Status
Terminated
Study Type
INTERVENTIONAL
Phases
PHASE4
Sponsor
Ipsen
Last Updated
December 15, 2025